OncoMatch/Clinical Trials/NCT07636824
Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study
Is NCT07636824 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Capecitabine or S-1 for extrahepatic cholangiocarcinoma and gallbladder carcinoma.
Treatment: Capecitabine or S-1
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: abdominal radiotherapy
Prior abdominal radiotherapy
Lab requirements
Blood counts
Neutrophils ≥1.0×10⁹/L, hemoglobin ≥80 g/L, platelets ≥100×10⁹/L
Kidney function
Creatinine and blood urea nitrogen ≤2.5×ULN
Liver function
Child-Pugh grade A5-B7; Total bilirubin <1.5×ULN; ALT and AST ≤2.5×ULN or ALT ≤1.5×ULN and AST ≤6×ULN (excluding AST elevation due to myocardial infarction)
Routine blood tests: Neutrophils ≥1.0×10⁹/L, hemoglobin ≥80 g/L, platelets ≥100×10⁹/L; Liver function: Child-Pugh grade A5-B7, Total bilirubin <1.5×ULN, ALT and AST ≤2.5×ULN or ALT ≤1.5×ULN and AST ≤6×ULN (excluding AST elevation due to myocardial infarction); Renal function: Creatinine and blood urea nitrogen ≤2.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07636824 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior abdominal radiotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages